亿帆医药(002019.SZ)：盐酸沙丙蝶呤散剂药品注册申请获受理

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Sichuan Defeng Pharmaceutical Co., Ltd., has received the acceptance notice for the domestic production drug registration application for Sodium Sapropterin Dihydrochloride Granules from the National Medical Products Administration (NMPA) [1] Group 1 - The drug Sodium Sapropterin Dihydrochloride Granules is intended to lower phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) caused by tetrahydrobiopterin (BH4) responsive phenylketonuria (PKU) [1] - The medication is applicable for adults and children over one month old [1] - The company submitted the drug registration application to the NMPA in September 2025 and received acceptance in the same month [1]